Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liraglutide vs OADs as Add-on to Metformin in Type 2 Diabetes (LIRA-PRIME)
NCT02730377Phase 4Completed
- Sponsor
- Novo Nordisk
- Start
- Mar 2016
- Primary completion
- Aug 2019
- Modality
- Peptides
- Countries
- 10
01
Overview
Phase 4, randomised, open-label trial of liraglutide in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Novo Nordisk. Primary endpoint: Time to Inadequate Glycaemic Control. Started Mar 2016; status: completed.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02730377.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02730377.